Please read full Prescribing Information for NUPLAZID, including Boxed WARNING.

Please read full Prescribing
Information for NUPLAZID, including Boxed WARNING.

 
 

prior authorization.

 

99% of prior authorizations on Medicare Part D plans only require a basic confirmation of diagnosis and/or a specialty prescriber.* If a patient needs prior authorization, complete the fields below, and then submit when enrolling your patient in Acadia Connect®.

*Formulary data current as of October 2023. Formulary status is subject to change. Please check with health plan to confirm.


Actor portrayals of a woman and man walking in an apple orchard in a heart shape

actor
portrayals

 
 

enroll your patients or residents.

To start these services for you and your patients or residents, complete our simple online prescription and enrollment form.

START ENROLLMENT
 
 
Connect with us:
1-844-737-2223
Mon.–Fri.,
8:00 am to
8:00 pm ET
 
 
 
Important Safety Information and Indication for NUPLAZID® (pimavanserin)
 

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

 
  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease.
 
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
  • Warnings and Precautions: QT Interval Prolongation
    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).
    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
  • Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
  • Drug Interactions:
    • Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.
 
Indication

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Dosage and Administration

Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.
 

Please read the full Prescribing Information, including Boxed WARNING.

 
< Support
BACK TO TOP